Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|172|5|1371-1383

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.172, Iss.5, 2015-05, pp. : 1371-1383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 13, Iss. 11, 2013-11 ,pp. : 2875-2883

John Wiley & Sons Inc

Access to resources Recommend Favorite

Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1552-1561

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stability of Successful Long-Term Adjustment in Alcohol Dependence: A Follow-Up Study 15 Years after the First Long-Term Follow-Up

By  

European Addiction Research, Vol. 10, Iss. 3, 2004-07 ,pp. : 126-132

Karger

Access to resources Recommend Favorite

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treating Patients with Autoimmune Pancreatitis: Results from a Long-Term Follow-Up Study

By  

Pancreatology, Vol. 5, Iss. 2-3, 2005-05 ,pp. : 234-240

Karger

Access to resources Recommend Favorite